Hansoh Pharmaceutical (03692) Announces HS-10541 Tablet Receives IND Approval from NMPA for Clinical Trials in KRAS G12C-Mutant Advanced Solid Tumors

Hansoh Pharma (03692) announced that HS-10541, a self-developed Class 1 new drug by the group, has received clinical trial approval from the National Medical Products Administration (NMPA) of China. The drug is intended to initiate clinical trials for "the treatment of advanced solid tumors with KRAS G12C mutations."